The short answer
Ask your prescriber before adding melatonin to clorazepate. Melatonin product information supports an alertness precaution, but it does not quantify this exact combination’s risk.
What this answer covers
Oral melatonin; prolonged-release product guidance is distinct from immediate-release supplements.
- Supplement or preparation
- Melatonin
- Medication ingredient
- clorazepate
Why adding melatonin needs review
The prolonged-release melatonin information cautions that benzodiazepine sedation may be enhanced. Clorazepate itself can impair alertness, so the prescriber should review the reason for adding another sleep product.
A study with another medicine has limits
A small surgical study found comparable sedation with alprazolam plus melatonin and alprazolam alone. That is useful context, but it did not test this medicine or long-term use at home.
Product and timing matter
Tell the prescriber whether the melatonin is immediate- or prolonged-release and list its dose and other ingredients. These sources do not establish a protective dosing gap.
Watch for impaired alertness
Clorazepate can affect alertness and coordination. Avoid driving if affected. Seek urgent help for severe difficulty waking or breathing, and tell the prescriber about alcohol, opioids and all other sedating products.
Evidence and practical considerations
Side effects & toxicity
Conditional sedation review is supported by melatonin product guidance and the exact medication CNS warning.
- Exact scope
- Oral melatonin; prolonged-release product guidance is distinct from immediate-release supplements. with Exact oral clorazepate dipotassium tablets. Rapid oral decarboxylation forms nordiazepam, with essentially no circulating parent; nordiazepam half-life about 40-50 hours. Human-serum-albumin binding of the swallowed parent is not an in vivo metabolite study. RxNorm IN 2353 relates to PIN 2607 dipotassium, matching the label.
- Medication form and route
- oral
- Timing or duration
- Source-specific single-dose, repeated-dose and observational exposures distinguished.
What remains uncertain
- No exact co-use study established by these sources. A short alprazolam trial is indirect, not a safety guarantee.
Factors that may matter: preparation and plant part; clinical indication; dose; other medicines; baseline alertness.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed oral clorazepate.
Can impair alertness and coordination; other CNS depressants can increase impairment. Opioid combinations have a specific respiratory-depression warning. Dependence and withdrawal require supervised changes. Rapid oral decarboxylation forms nordiazepam, with essentially no circulating parent; nordiazepam half-life about 40-50 hours. Human-serum-albumin binding of the swallowed parent is not an in vivo metabolite study. RxNorm IN 2353 relates to PIN 2607 dipotassium, matching the label.
How this applies: Exact IN and labeled oral formulation; route, salt and metabolite distinctions retained.
No quantified risk for every herb or universal protective spacing interval. Opioid-specific evidence does not prove equal botanical respiratory risk.
Source 2: product label
medicines.org.uk · Source check Sep 10, 2026
Population: People considering the specified supplement.
Prolonged-release melatonin product information cautions that benzodiazepine sedation may be enhanced. Its measured interaction study involved zolpidem.
How this applies: Preparation-specific class precaution, not a directly measured interaction with clorazepate.
Class precaution and a zolpidem study, not direct evidence for this exact benzodiazepine. Immediate-release and prolonged-release preparations differ.
Source 3: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Eighty selected surgical patients, twenty per arm.
Measured sedation and amnesia were comparable between combination and alprazolam alone.
How this applies: Original named medication and preparation only; indirect evidence for clorazepate. Comparator arms are not coadministration.
Small perioperative study, not powered for adverse events and not a chronic at-home safety test; exclusions included obesity and neuropsychiatric disease. Some pairwise significance reporting is internally inconsistent, so no superiority claim is relied on.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Current exact available claims adjudicated using original captures and explicit identity and comparator limits. | |
| Research summary published |
Article revision: fb9fc971272b8bdd
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.